PMID-sentid	Pub_year	Sent_text	compound_name	comp_offset	prot_official_name	organism	prot_offset
24533473-2	2014	Quantitative chemoproteomic profiling shows that LY294002 and LY303511, a close analogue devoid of PI3K activity, inhibit the BET bromodomain proteins BRD2, BRD3, and BRD4 that comprise a family of targets structurally unrelated to PI3K.	LY 303511	62-70	delta/notch like EGF repeat containing	Homo sapiens	126-129
24533473-2	2014	Quantitative chemoproteomic profiling shows that LY294002 and LY303511, a close analogue devoid of PI3K activity, inhibit the BET bromodomain proteins BRD2, BRD3, and BRD4 that comprise a family of targets structurally unrelated to PI3K.	LY 303511	62-70	bromodomain containing 2	Homo sapiens	151-155
24533473-2	2014	Quantitative chemoproteomic profiling shows that LY294002 and LY303511, a close analogue devoid of PI3K activity, inhibit the BET bromodomain proteins BRD2, BRD3, and BRD4 that comprise a family of targets structurally unrelated to PI3K.	LY 303511	62-70	bromodomain containing 3	Homo sapiens	157-161
24533473-2	2014	Quantitative chemoproteomic profiling shows that LY294002 and LY303511, a close analogue devoid of PI3K activity, inhibit the BET bromodomain proteins BRD2, BRD3, and BRD4 that comprise a family of targets structurally unrelated to PI3K.	LY 303511	62-70	bromodomain containing 4	Homo sapiens	167-171
24176848-4	2013	We provide evidence that upon treatment with LY303511, Hsp27 is progressively sequestered in the nucleus, thus reducing its protective effect in the cytosol during the apoptotic process.	LY 303511	45-53	heat shock protein family B (small) member 1	Homo sapiens	55-60
24176848-5	2013	LY303511-induced nuclear translocation of Hsp27 is linked to its sustained phosphorylation via activation of p38 kinase and MAPKAP kinase 2 and the inhibition of PP2A.	LY 303511	0-8	heat shock protein family B (small) member 1	Homo sapiens	42-47
24176848-2	2013	We report here a novel mechanism underlying the tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) sensitizing activity of the small molecule LY303511, an inactive analog of the phosphoinositide 3-kinase inhibitor inhibitor LY294002, in HeLa cells that are refractory to TRAIL-induced apoptosis.	LY 303511	155-163	TNF superfamily member 10	Homo sapiens	48-103
24176848-2	2013	We report here a novel mechanism underlying the tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) sensitizing activity of the small molecule LY303511, an inactive analog of the phosphoinositide 3-kinase inhibitor inhibitor LY294002, in HeLa cells that are refractory to TRAIL-induced apoptosis.	LY 303511	155-163	TNF superfamily member 10	Homo sapiens	105-110
24176848-5	2013	LY303511-induced nuclear translocation of Hsp27 is linked to its sustained phosphorylation via activation of p38 kinase and MAPKAP kinase 2 and the inhibition of PP2A.	LY 303511	0-8	MAPK activated protein kinase 2	Homo sapiens	124-139
24176848-2	2013	We report here a novel mechanism underlying the tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) sensitizing activity of the small molecule LY303511, an inactive analog of the phosphoinositide 3-kinase inhibitor inhibitor LY294002, in HeLa cells that are refractory to TRAIL-induced apoptosis.	LY 303511	155-163	TNF superfamily member 10	Homo sapiens	284-289
24176848-5	2013	LY303511-induced nuclear translocation of Hsp27 is linked to its sustained phosphorylation via activation of p38 kinase and MAPKAP kinase 2 and the inhibition of PP2A.	LY 303511	0-8	protein phosphatase 2 phosphatase activator	Homo sapiens	162-166
24176848-7	2013	Furthermore, genetic manipulation of Hsp27 expression significantly affected the TRAIL sensitizing activity of LY303511, which corroborated the Hsp27 targeting activity of LY303511.	LY 303511	111-119	heat shock protein family B (small) member 1	Homo sapiens	37-42
24176848-7	2013	Furthermore, genetic manipulation of Hsp27 expression significantly affected the TRAIL sensitizing activity of LY303511, which corroborated the Hsp27 targeting activity of LY303511.	LY 303511	111-119	TNF superfamily member 10	Homo sapiens	81-86
24176848-7	2013	Furthermore, genetic manipulation of Hsp27 expression significantly affected the TRAIL sensitizing activity of LY303511, which corroborated the Hsp27 targeting activity of LY303511.	LY 303511	111-119	heat shock protein family B (small) member 1	Homo sapiens	144-149
24176848-7	2013	Furthermore, genetic manipulation of Hsp27 expression significantly affected the TRAIL sensitizing activity of LY303511, which corroborated the Hsp27 targeting activity of LY303511.	LY 303511	172-180	heat shock protein family B (small) member 1	Homo sapiens	37-42
24176848-7	2013	Furthermore, genetic manipulation of Hsp27 expression significantly affected the TRAIL sensitizing activity of LY303511, which corroborated the Hsp27 targeting activity of LY303511.	LY 303511	172-180	TNF superfamily member 10	Homo sapiens	81-86
24176848-7	2013	Furthermore, genetic manipulation of Hsp27 expression significantly affected the TRAIL sensitizing activity of LY303511, which corroborated the Hsp27 targeting activity of LY303511.	LY 303511	172-180	heat shock protein family B (small) member 1	Homo sapiens	144-149
22982511-0	2012	Reactive oxygen species (ROS) and sensitization to TRAIL-induced apoptosis, in Bayesian network modelling of HeLa cell response to LY303511.	LY 303511	131-139	TNF superfamily member 10	Homo sapiens	51-56
23239672-9	2013	Surprisingly, caspase-8 exhibited a transient decrease in activity after LY30 treatment, prior to strong activation.	LY 303511	73-77	caspase 8	Homo sapiens	14-23
23239672-10	2013	cFLIP, an inhibitor of caspase-8 activation, was up-regulated briefly after 30 min of LY30 treatment, followed by a significant down-regulation over prolonged exposure.	LY 303511	86-90	caspase 8	Homo sapiens	23-32
22982511-1	2012	BACKGROUND: The compound LY303511 (LY30) has been proven to induce production of ROS and to sensitize cancer cells to TRAIL-induced apoptosis, but the mechanisms and mediators of LY30-induced effects are potentially complex.	LY 303511	25-33	TNF superfamily member 10	Homo sapiens	118-123
22982511-1	2012	BACKGROUND: The compound LY303511 (LY30) has been proven to induce production of ROS and to sensitize cancer cells to TRAIL-induced apoptosis, but the mechanisms and mediators of LY30-induced effects are potentially complex.	LY 303511	25-29	TNF superfamily member 10	Homo sapiens	118-123
22982511-1	2012	BACKGROUND: The compound LY303511 (LY30) has been proven to induce production of ROS and to sensitize cancer cells to TRAIL-induced apoptosis, but the mechanisms and mediators of LY30-induced effects are potentially complex.	LY 303511	35-39	TNF superfamily member 10	Homo sapiens	118-123
22982511-10	2012	In cell viability experiments, the additive effects of calcium and peroxynitrite were responsible for 90% of LY30-mediated sensitization to TRAIL-induced apoptosis.	LY 303511	109-113	TNF superfamily member 10	Homo sapiens	140-145
18657281-5	2008	LY303511 (LY30), a structural analogue and a negative control for PI3K inhibitory activity of LY29, also suppressed COX-2 induction.	LY 303511	0-8	mitochondrially encoded cytochrome c oxidase II	Homo sapiens	116-121
21098703-6	2010	Treatment of cells with the well-known PI3K inhibitor LY294002, and its structural analogue LY303511, which does not inhibit PI3K, increased homotypic GJIC; however, we found the effect to be independent of PI3K/AKT inhibition.	LY 303511	92-100	AKT serine/threonine kinase 1	Homo sapiens	212-215
19641096-8	2009	Both LY-294002 (100 microM), an inhibitor of PI3 kinases, and its inactive analog LY-303511 (100 microM) rapidly and reversibly inhibited Kir current, suggesting that these compounds act as direct channel blockers.	LY 303511	82-91	killer cell immunoglobulin like receptor, two Ig domains and long cytoplasmic tail 4	Homo sapiens	138-141
19223550-0	2009	LY303511 enhances TRAIL sensitivity of SHEP-1 neuroblastoma cells via hydrogen peroxide-mediated mitogen-activated protein kinase activation and up-regulation of death receptors.	LY 303511	0-8	TNF superfamily member 10	Homo sapiens	18-23
19223550-0	2009	LY303511 enhances TRAIL sensitivity of SHEP-1 neuroblastoma cells via hydrogen peroxide-mediated mitogen-activated protein kinase activation and up-regulation of death receptors.	LY 303511	0-8	SH2 domain containing 3C	Homo sapiens	39-45
19223550-2	2009	Here, we investigated the mechanism of LY30-induced sensitization of human neuroblastoma cells to TRAIL-mediated apoptosis.	LY 303511	39-43	TNF superfamily member 10	Homo sapiens	98-103
19223550-3	2009	We provide evidence that LY30-induced increase in intracellular H(2)O(2) up-regulates the expression of TRAIL receptors (DR4 and DR5) in SHEP-1 cells by activating mitogen-activated protein kinases, resulting in a significant amplification of TRAIL-mediated caspase-8 processing and activity, cytosolic translocation of cytochrome c, and cell death.	LY 303511	25-29	TNF superfamily member 10	Homo sapiens	104-109
19223550-3	2009	We provide evidence that LY30-induced increase in intracellular H(2)O(2) up-regulates the expression of TRAIL receptors (DR4 and DR5) in SHEP-1 cells by activating mitogen-activated protein kinases, resulting in a significant amplification of TRAIL-mediated caspase-8 processing and activity, cytosolic translocation of cytochrome c, and cell death.	LY 303511	25-29	major histocompatibility complex, class II, DR beta 4	Homo sapiens	121-124
19223550-3	2009	We provide evidence that LY30-induced increase in intracellular H(2)O(2) up-regulates the expression of TRAIL receptors (DR4 and DR5) in SHEP-1 cells by activating mitogen-activated protein kinases, resulting in a significant amplification of TRAIL-mediated caspase-8 processing and activity, cytosolic translocation of cytochrome c, and cell death.	LY 303511	25-29	TNF receptor superfamily member 10b	Homo sapiens	129-132
19223550-3	2009	We provide evidence that LY30-induced increase in intracellular H(2)O(2) up-regulates the expression of TRAIL receptors (DR4 and DR5) in SHEP-1 cells by activating mitogen-activated protein kinases, resulting in a significant amplification of TRAIL-mediated caspase-8 processing and activity, cytosolic translocation of cytochrome c, and cell death.	LY 303511	25-29	SH2 domain containing 3C	Homo sapiens	137-143
19223550-3	2009	We provide evidence that LY30-induced increase in intracellular H(2)O(2) up-regulates the expression of TRAIL receptors (DR4 and DR5) in SHEP-1 cells by activating mitogen-activated protein kinases, resulting in a significant amplification of TRAIL-mediated caspase-8 processing and activity, cytosolic translocation of cytochrome c, and cell death.	LY 303511	25-29	TNF superfamily member 10	Homo sapiens	243-248
19223550-3	2009	We provide evidence that LY30-induced increase in intracellular H(2)O(2) up-regulates the expression of TRAIL receptors (DR4 and DR5) in SHEP-1 cells by activating mitogen-activated protein kinases, resulting in a significant amplification of TRAIL-mediated caspase-8 processing and activity, cytosolic translocation of cytochrome c, and cell death.	LY 303511	25-29	caspase 8	Homo sapiens	258-267
19223550-3	2009	We provide evidence that LY30-induced increase in intracellular H(2)O(2) up-regulates the expression of TRAIL receptors (DR4 and DR5) in SHEP-1 cells by activating mitogen-activated protein kinases, resulting in a significant amplification of TRAIL-mediated caspase-8 processing and activity, cytosolic translocation of cytochrome c, and cell death.	LY 303511	25-29	cytochrome c, somatic	Homo sapiens	320-332
19223550-4	2009	Involvement of the death receptors was further confirmed by the ability of blocking antibodies against DR4 and/or DR5 to inhibit LY30-induced TRAIL sensitization.	LY 303511	129-133	major histocompatibility complex, class II, DR beta 4	Homo sapiens	103-106
19223550-4	2009	Involvement of the death receptors was further confirmed by the ability of blocking antibodies against DR4 and/or DR5 to inhibit LY30-induced TRAIL sensitization.	LY 303511	129-133	TNF receptor superfamily member 10b	Homo sapiens	114-117
19223550-4	2009	Involvement of the death receptors was further confirmed by the ability of blocking antibodies against DR4 and/or DR5 to inhibit LY30-induced TRAIL sensitization.	LY 303511	129-133	TNF superfamily member 10	Homo sapiens	142-147
19223550-5	2009	Pharmacologic inhibition of c-Jun NH(2) terminal kinase (JNK) and extracellular signal-regulated kinase (ERK) activation by SP600125 and PD98059, respectively, blocked LY30-induced increase in sensitization to TRAIL-mediated death.	LY 303511	168-172	mitogen-activated protein kinase 8	Homo sapiens	28-55
19223550-5	2009	Pharmacologic inhibition of c-Jun NH(2) terminal kinase (JNK) and extracellular signal-regulated kinase (ERK) activation by SP600125 and PD98059, respectively, blocked LY30-induced increase in sensitization to TRAIL-mediated death.	LY 303511	168-172	mitogen-activated protein kinase 8	Homo sapiens	57-60
19223550-5	2009	Pharmacologic inhibition of c-Jun NH(2) terminal kinase (JNK) and extracellular signal-regulated kinase (ERK) activation by SP600125 and PD98059, respectively, blocked LY30-induced increase in sensitization to TRAIL-mediated death.	LY 303511	168-172	mitogen-activated protein kinase 1	Homo sapiens	66-103
19223550-5	2009	Pharmacologic inhibition of c-Jun NH(2) terminal kinase (JNK) and extracellular signal-regulated kinase (ERK) activation by SP600125 and PD98059, respectively, blocked LY30-induced increase in sensitization to TRAIL-mediated death.	LY 303511	168-172	mitogen-activated protein kinase 1	Homo sapiens	105-108
19223550-5	2009	Pharmacologic inhibition of c-Jun NH(2) terminal kinase (JNK) and extracellular signal-regulated kinase (ERK) activation by SP600125 and PD98059, respectively, blocked LY30-induced increase in sensitization to TRAIL-mediated death.	LY 303511	168-172	TNF superfamily member 10	Homo sapiens	210-215
19223550-6	2009	Finally, small interfering RNA-mediated gene silencing of JNK and ERK inhibited LY30-induced increase in surface expression of DR4 and DR5, respectively.	LY 303511	80-84	mitogen-activated protein kinase 8	Homo sapiens	58-61
19223550-6	2009	Finally, small interfering RNA-mediated gene silencing of JNK and ERK inhibited LY30-induced increase in surface expression of DR4 and DR5, respectively.	LY 303511	80-84	mitogen-activated protein kinase 1	Homo sapiens	66-69
19223550-6	2009	Finally, small interfering RNA-mediated gene silencing of JNK and ERK inhibited LY30-induced increase in surface expression of DR4 and DR5, respectively.	LY 303511	80-84	major histocompatibility complex, class II, DR beta 4	Homo sapiens	127-130
19223550-6	2009	Finally, small interfering RNA-mediated gene silencing of JNK and ERK inhibited LY30-induced increase in surface expression of DR4 and DR5, respectively.	LY 303511	80-84	TNF receptor superfamily member 10b	Homo sapiens	135-138
19223550-7	2009	These data show that JNK and ERK are two crucial players involved in H(2)O(2)-mediated increase in TRAIL sensitization of tumor cells upon exposure to LY30 and underscore a novel mode of action of this inactive analogue of LY29.	LY 303511	151-155	mitogen-activated protein kinase 8	Homo sapiens	21-24
19223550-7	2009	These data show that JNK and ERK are two crucial players involved in H(2)O(2)-mediated increase in TRAIL sensitization of tumor cells upon exposure to LY30 and underscore a novel mode of action of this inactive analogue of LY29.	LY 303511	151-155	mitogen-activated protein kinase 1	Homo sapiens	29-32
19223550-7	2009	These data show that JNK and ERK are two crucial players involved in H(2)O(2)-mediated increase in TRAIL sensitization of tumor cells upon exposure to LY30 and underscore a novel mode of action of this inactive analogue of LY29.	LY 303511	151-155	TNF superfamily member 10	Homo sapiens	99-104
18831964-2	2008	Both LY29 and its inactive analogue, LY303511 (LY30), significantly up-regulated early growth response gene 1 (Egr-1) expression in HL-60 leukemic cells.	LY 303511	37-45	early growth response 1	Homo sapiens	111-116
18831964-2	2008	Both LY29 and its inactive analogue, LY303511 (LY30), significantly up-regulated early growth response gene 1 (Egr-1) expression in HL-60 leukemic cells.	LY 303511	37-41	early growth response 1	Homo sapiens	111-116
18657281-5	2008	LY303511 (LY30), a structural analogue and a negative control for PI3K inhibitory activity of LY29, also suppressed COX-2 induction.	LY 303511	0-4	mitochondrially encoded cytochrome c oxidase II	Homo sapiens	116-121
17585340-0	2007	LY303511 amplifies TRAIL-induced apoptosis in tumor cells by enhancing DR5 oligomerization, DISC assembly, and mitochondrial permeabilization.	LY 303511	0-8	TNF superfamily member 10	Homo sapiens	19-24
17585340-0	2007	LY303511 amplifies TRAIL-induced apoptosis in tumor cells by enhancing DR5 oligomerization, DISC assembly, and mitochondrial permeabilization.	LY 303511	0-8	TNF receptor superfamily member 10b	Homo sapiens	71-74
17585340-4	2007	Intrigued by these findings, we investigated the effect of LY303511 on TRAIL-induced apoptosis in HeLa cells.	LY 303511	59-67	TNF superfamily member 10	Homo sapiens	71-76
17532611-8	2007	Rac1 is known to mediate signalling between the phosphatidylinositol-3 kinase (PI-3K) product and NADPH oxidase, and treatment with LY24002 (10 microM), a highly selective inhibitor of PI-3K, completely attenuated ROS production in response to both PIF and Ang II, and inhibited total protein degradation, while the inactive analogue LY303511 (100 microM) had no effect.	LY 303511	334-342	Rac family small GTPase 1	Mus musculus	0-4
18523362-5	2007	RESULTS: PI3K inhibitors LY294002 and LY303511 were shown to suppress TNF-alpha expression that is stimulated by GM3 in B16 cells, suggesting that the GM3 signal is located upstream of the PI3K-Akt pathway.	LY 303511	38-46	eiger	Drosophila melanogaster	70-79
18523362-5	2007	RESULTS: PI3K inhibitors LY294002 and LY303511 were shown to suppress TNF-alpha expression that is stimulated by GM3 in B16 cells, suggesting that the GM3 signal is located upstream of the PI3K-Akt pathway.	LY 303511	38-46	granulocyte macrophage antigen 3	Mus musculus	113-116
18523362-5	2007	RESULTS: PI3K inhibitors LY294002 and LY303511 were shown to suppress TNF-alpha expression that is stimulated by GM3 in B16 cells, suggesting that the GM3 signal is located upstream of the PI3K-Akt pathway.	LY 303511	38-46	granulocyte macrophage antigen 3	Mus musculus	151-154
18523362-5	2007	RESULTS: PI3K inhibitors LY294002 and LY303511 were shown to suppress TNF-alpha expression that is stimulated by GM3 in B16 cells, suggesting that the GM3 signal is located upstream of the PI3K-Akt pathway.	LY 303511	38-46	thymoma viral proto-oncogene 1	Mus musculus	194-197
16704410-4	2006	The induction of heme oxygenase-1 in renal adenocarcinoma cells was blocked by actinomycin D and cycloheximide and was abolished by the phosphatidylinositol 3-kinase inhibitor, LY294002, but not by the inactive analog LY303511.	LY 303511	218-226	heme oxygenase 1	Mus musculus	17-33
15923340-0	2005	LY303511 (2-piperazinyl-8-phenyl-4H-1-benzopyran-4-one) acts via phosphatidylinositol 3-kinase-independent pathways to inhibit cell proliferation via mammalian target of rapamycin (mTOR)- and non-mTOR-dependent mechanisms.	LY 303511	0-8	phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit delta	Homo sapiens	65-94
15923340-0	2005	LY303511 (2-piperazinyl-8-phenyl-4H-1-benzopyran-4-one) acts via phosphatidylinositol 3-kinase-independent pathways to inhibit cell proliferation via mammalian target of rapamycin (mTOR)- and non-mTOR-dependent mechanisms.	LY 303511	0-8	mechanistic target of rapamycin kinase	Homo sapiens	150-179
15923340-0	2005	LY303511 (2-piperazinyl-8-phenyl-4H-1-benzopyran-4-one) acts via phosphatidylinositol 3-kinase-independent pathways to inhibit cell proliferation via mammalian target of rapamycin (mTOR)- and non-mTOR-dependent mechanisms.	LY 303511	0-8	mechanistic target of rapamycin kinase	Homo sapiens	181-185
15923340-0	2005	LY303511 (2-piperazinyl-8-phenyl-4H-1-benzopyran-4-one) acts via phosphatidylinositol 3-kinase-independent pathways to inhibit cell proliferation via mammalian target of rapamycin (mTOR)- and non-mTOR-dependent mechanisms.	LY 303511	0-8	mechanistic target of rapamycin kinase	Homo sapiens	196-200
15923340-0	2005	LY303511 (2-piperazinyl-8-phenyl-4H-1-benzopyran-4-one) acts via phosphatidylinositol 3-kinase-independent pathways to inhibit cell proliferation via mammalian target of rapamycin (mTOR)- and non-mTOR-dependent mechanisms.	LY 303511	10-54	phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit delta	Homo sapiens	65-94
15923340-0	2005	LY303511 (2-piperazinyl-8-phenyl-4H-1-benzopyran-4-one) acts via phosphatidylinositol 3-kinase-independent pathways to inhibit cell proliferation via mammalian target of rapamycin (mTOR)- and non-mTOR-dependent mechanisms.	LY 303511	10-54	mechanistic target of rapamycin kinase	Homo sapiens	150-179
15923340-0	2005	LY303511 (2-piperazinyl-8-phenyl-4H-1-benzopyran-4-one) acts via phosphatidylinositol 3-kinase-independent pathways to inhibit cell proliferation via mammalian target of rapamycin (mTOR)- and non-mTOR-dependent mechanisms.	LY 303511	10-54	mechanistic target of rapamycin kinase	Homo sapiens	181-185
15923340-0	2005	LY303511 (2-piperazinyl-8-phenyl-4H-1-benzopyran-4-one) acts via phosphatidylinositol 3-kinase-independent pathways to inhibit cell proliferation via mammalian target of rapamycin (mTOR)- and non-mTOR-dependent mechanisms.	LY 303511	10-54	mechanistic target of rapamycin kinase	Homo sapiens	196-200
15923340-5	2005	We hypothesized that a close structural analog, 2-piperazinyl-8-phenyl-4H-1-benzopyran-4-one (LY303511) might inhibit mTOR-dependent cell proliferation without unwanted effects on PI3K.	LY 303511	48-92	mechanistic target of rapamycin kinase	Homo sapiens	118-122
15923340-5	2005	We hypothesized that a close structural analog, 2-piperazinyl-8-phenyl-4H-1-benzopyran-4-one (LY303511) might inhibit mTOR-dependent cell proliferation without unwanted effects on PI3K.	LY 303511	94-102	mechanistic target of rapamycin kinase	Homo sapiens	118-122
15923340-6	2005	In human lung epithelial adenocarcinoma (A549) cells, LY303511, like rapamycin, inhibited mTOR-dependent phosphorylation of S6K, but not PI3K-dependent phosphorylation of Akt.	LY 303511	54-62	mechanistic target of rapamycin kinase	Homo sapiens	90-94
15923340-9	2005	Consistent with an additional mTOR-independent kinase target, LY303511 inhibited casein kinase 2 activity, a known regulator of G(1) and G(2)/M progression.	LY 303511	62-70	mechanistic target of rapamycin kinase	Homo sapiens	30-34
15923340-11	2005	Given its inhibition of cell proliferation via mTOR-dependent and independent mechanisms, LY303511 has therapeutic potential with antineoplastic actions that are independent of PI3K inhibition.	LY 303511	90-98	mechanistic target of rapamycin kinase	Homo sapiens	47-51
15894110-5	2005	LY303511, an inactive analogue of LY294002, also inhibited NO production and iNOS expression.	LY 303511	0-8	nitric oxide synthase 2, inducible	Mus musculus	77-81
14960322-4	2004	LY303511 (LY30), an inactive analogue of LY29, also inhibited MCP-1 expression.	LY 303511	0-8	C-C motif chemokine ligand 2	Homo sapiens	62-67
14960322-4	2004	LY303511 (LY30), an inactive analogue of LY29, also inhibited MCP-1 expression.	LY 303511	0-4	C-C motif chemokine ligand 2	Homo sapiens	62-67
14960322-5	2004	LY29 and LY30 inhibited activation of nuclear factor-kappaB (NF-kappaB).	LY 303511	9-13	nuclear factor kappa B subunit 1	Homo sapiens	38-59
14960322-5	2004	LY29 and LY30 inhibited activation of nuclear factor-kappaB (NF-kappaB).	LY 303511	9-13	nuclear factor kappa B subunit 1	Homo sapiens	61-70
12586735-6	2003	Kv2.1 and Kv1.4 are highly expressed in beta-cells, and in Kv2.1-transfected tsA201 cells, 50 microM LY294002 and 100 microM LY303511 reversibly inhibited currents by 99% and 41%, respectively.	LY 303511	125-133	potassium voltage-gated channel subfamily B member 1	Homo sapiens	0-5
12586735-6	2003	Kv2.1 and Kv1.4 are highly expressed in beta-cells, and in Kv2.1-transfected tsA201 cells, 50 microM LY294002 and 100 microM LY303511 reversibly inhibited currents by 99% and 41%, respectively.	LY 303511	125-133	potassium voltage-gated channel subfamily A member 4	Homo sapiens	10-15
12586735-6	2003	Kv2.1 and Kv1.4 are highly expressed in beta-cells, and in Kv2.1-transfected tsA201 cells, 50 microM LY294002 and 100 microM LY303511 reversibly inhibited currents by 99% and 41%, respectively.	LY 303511	125-133	potassium voltage-gated channel subfamily B member 1	Homo sapiens	59-64